<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Our step-wise approach to the evaluation and initial management of cervical lymphadenopathy in children that does not appear to be caused by an infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Our step-wise approach to the evaluation and initial management of cervical lymphadenopathy in children that does not appear to be caused by an infection</h1>
<div class="graphic"><div class="figure"><div class="ttl">Our step-wise approach to the evaluation and initial management of cervical lymphadenopathy in children that does not appear to be caused by an infection</div><div class="cntnt"><table cellspacing="0"><tbody> <tr class="divider_bottom"> <td>1. History and examination to look for obvious causes or worrisome features*</td> </tr> <tr class="divider_bottom"> <td>2. Refer children with worrisome features for early biopsy<sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td>3. Evaluate and treat causes that appear obvious based on initial evaluation</td> </tr> <tr class="divider_bottom"> <td>4. When the cause remains uncertain after the initial evaluation: <ul class="decimal_heading"> <li>Lymph node &lt;2 cm (0.8 inches) in longest diameter: <ul> <li>Observe for 10 to 14 days: <ul> <li>Regression in size – No additional evaluation or therapy </li> <li>No regression in size: <ul> <li>Obtain CBC/differential; ESR/CRP; serology for EBV, CMV, and HIV; evaluate for Kawasaki disease and other uncommon causes of cervical lymphadenopathy as indicated by the history and examination<sup>Δ</sup> </li> <li>Provide referral or treatment as indicated based upon results </li> </ul> </li> </ul> </li> </ul> </li> <li>Lymph node ≥2 cm (0.8 inches) in longest diameter <ul> <li>Obtain CBC, ESR/CRP, and chest radiograph  <ul> <li>Worrisome features* – Refer for biopsy </li> <li>No worrisome features and cause remains uncertain (including possible occult infection) – Perform TST and provide 10- to 14-day trial of antibiotics<sup>◊</sup> <ul> <li>TST positive – Additional testing may be necessary to establish diagnosis of tuberculosis or nontuberculous mycobacteria </li> <li>TST negative and lymph node regresses in size – No additional evaluation or therapy </li> <li>TST negative and lymph node does not regress: <ul> <li>Obtain serology for EBV, CMV, and HIV; evaluate for Kawasaki disease and other uncommon causes of cervical lymphadenopathy as indicated by the history and examination<sup>Δ</sup> </li> <li>Provide referral or treatment as indicated based upon results </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td>5. Obtain biopsy<sup>¶</sup> after 4 weeks if the diagnosis remains uncertain and the lymph node has not regressed in size or there is no response to antimicrobial therapy/broadened antimicrobial therapy<sup>§</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; EBV: Epstein-Barr virus; CMV: cytomegalovirus; TST: tuberculin skin test; CA-MRSA: community-associated methicillin-resistant <em>Staphylococcus aureus</em>.<br/>* Worrisome features include: systemic symptoms (fever &gt;1 week, night sweats, weight loss [&gt;10% of body weight]), fixed nontender nodes in the absence of other symptoms; abnormal chest radiograph (eg, mediastinal mass or hilar adenopathy), abnormal CBC/differential, lack of upper respiratory tract symptoms, lymph nodes &gt;2 cm in diameter that have increased in size from baseline or have not responded to 2 weeks of antibiotic therapy, and persistently elevated ESR/CRP or rising ESR/CRP despite antibiotic therapy.<br/>¶ Excisional biopsy is preferred; fine-needle aspirate biopsies usually are inadequate for evaluation of pediatric malignancies or infiltrative diseases.<br/>Δ Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.<br/>◊ Empiric antibiotic therapy should include coverage for common pathogens such as group A <em innerhtml="">Streptococcus </em>and <em>Staphylococcus</em><em innerhtml=""> aureus </em>(eg, clindamycin in areas with a high prevalence of CA-MRSA or a first-generation cephalosporin [eg, cephalexin] or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA). If the patient's systemic symptoms (eg, fever) do not improve within 72 hours or the lymph node increases in size (at any point during treatment), we broaden the antimicrobial coverage to include coverage for common pathogens that were not included initially (eg, CA-MRSA, <em innerhtml="">Bartonella henselae </em>[for children with exposure to cats or kittens]). Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details. <br/>§ For lymph nodes &lt;2 cm (0.8 inches) in diameter, continued observation may be reasonable if there are no worrisome features.</div><div id="graphicVersion">Graphic 106347 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
